布地奈德联合特布他林治疗支气管哮喘的临床观察

发布时间：2018-03-20 03:01

本文选题：布地奈德　切入点：特布他林　出处：《中国药房》2015年06期 　论文类型：期刊论文

【摘要】：目的:观察布地奈德联合特布他林治疗支气管哮喘的临床疗效和安全性。方法:80例支气管哮喘患者随机均分为对照组和观察组。两组患者均给予常规综合治疗,包括吸氧、止咳、平喘、祛痰、抗感染等。在此基础上,对照组患者给予布地奈德混悬液1 ml(含布地奈德0.5 mg)加入2 ml 0.9%氯化钠注射液中雾化吸入,10~15 min/次,bid,早晚进行;观察组患者在对照组治疗的基础上给予特布他林雾化液1 ml(含特布他林2.5 mg)加入2 ml 0.9%氯化钠注射液中雾化吸入,10~15 min/次,bid,早晚进行。两组患者疗程均为7 d。观察两组患者的临床疗效,治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、FEV1占预计值的百分比(FEV1%)、最大呼气峰流速(PEF)],临床症状消失时间(气促消失时间、憋喘消失时间、哮鸣音消失时间、咳嗽消失时间)及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P0.05)。治疗前两组患者肺功能指标比较,差异均无统计学意义(P0.05);治疗后两组患者肺功能指标均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P0.05)。观察组患者气促消失时间、憋喘消失时间、哮鸣音消失时间、咳嗽消失时间均显著短于对照组,两组比较差异有统计学意义(P0.05)。两组患者治疗期间均未见明显不良反应发生。结论:布地奈德联合特布他林治疗支气管哮喘较单用布地奈德疗效更好,安全性相似。
[Abstract]:Objective: to observe the clinical efficacy and safety of budesonide combined with terbutaline in the treatment of bronchial asthma. The patients in the control group were given budesonide suspension 1 ml (including budesonide 0. 5 mg) and 2 ml 0.9% sodium chloride injection. The patients in the observation group were given terbutaline aerosol solution 1 ml (containing terbutaline 2.5 mg) and 2 ml 0.9% sodium chloride injection on the basis of the treatment in the control group. The patients in the observation group were given 10 ~ 15 min/ of nebulized inhalation for 10 ~ 15 min/ respectively. The course of treatment in both groups was 7 days. The clinical efficacy of the two groups, Pulmonary function index before and after treatment [forced expiratory volume of 1 seconds FEV1 / FEV1 as a percentage of predicted value, FEV1, PEF), time of disappearance of clinical symptoms (time of disappearance of shortness of breath, time of dyspnea disappearance, time of disappearance of wheezing, time of disappearance of wheezing, time of disappearance of wheezing), time of disappearance of clinical symptoms, Results: the total effective rate in the observation group was significantly higher than that in the control group, and the difference between the two groups was statistically significant (P 0.05). After treatment, the pulmonary function indexes of the two groups were significantly higher than those of the same group and the observation group was higher than that of the control group, and the difference was statistically significant (P 0.05). The time of shortness of breath and dyspnea disappeared in the observation group was significantly higher than that in the control group. The time of disappearance of wheezing and cough was significantly shorter than that of control group. The difference between the two groups was statistically significant (P 0.05). No significant adverse reactions occurred in the two groups during treatment. Conclusion: budesonide combined with terbutaline is more effective and safe than budesonide alone in the treatment of bronchial asthma.
【作者单位】：四川省医学科学院/四川省人民医院老年科;
【分类号】：R562.25

【参考文献】